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Summary Mucocutaneousleishmaniasis(MCL)isanimportanthealthprobleminmanyruralareasofLatinAmerica,
but there are few data on the results of programmatic approaches to control the disease. We report the
results of a control programme in San Martin de Pangoa District, which reports one of the highest
prevalences of MCL in Peru. For 2 years (2001–2002), the technicians at the health post were trained in
patient case management, received medical support and were supplied with antimonials. An evaluation
after 2 years showed the following main achievements: better diagnosis of patients, who were conﬁrmed
by microscopy in 34% (82/240) of the cases in 2001 and 60% of the cases (153/254) in 2002;
improved follow-up during treatment: 237 of 263 (90%) patients who initiated an antimonial therapy
ended the full treatment course; improved follow-up after treatment: 143 of 237 (60%) patients who
ended their full treatment were correctly monitored during the required period of 6 (cutaneous cases) or
12 (mucosal cases) months after the end of treatment. These achievements were largely due to the human
andlogisticalresourcesmadeavailable,theconstantavailabilityofmedicationsandtheclosecollaboration
between the Ministry of Health, a national research institute and an international non-governmental
organization. At the end of this period, the health authorities decided to register a generic brand of
sodium stibogluconate, which is now in use. This should allow the treatment of a signiﬁcant number of
additional patients, while saving money to invest in other facets of the case management.
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Introduction
Mucocutaneous leishmaniasis (MCL), caused by Leish-
mania (Viannia) braziliensis, is endemic in Peru and affects
the populations living in the tropical rain forest in the
eastern part of the Andes (Lucas et al. 1998). The initial
lesion comprises a cutaneous nodular and inﬁltrative lesion
frequently leading to ulceration with raised edges, which
causes little pain and usually heals spontaneously (Davies
et al. 2003). Diagnosis is based on directly evidencing the
parasite in the lesions through microscopical examinations
of Giemsa-stained smears (Dimier-David et al. 1991) and/
or in demonstration the parasite in in vitro cultures and/or
by PCR methods (Lopez et al. 1993). The standard
treatment of these lesions is daily injections of pentavalent
antimony for 20 days, available as either Pentostam 
(sodium stibogluconate, GSK) or Glucantime  (meglu-
mine antimoniate, Aventis) (Croft & Yardley 2002). In
addition to being painful when administrated intramuscu-
larly and relatively toxic, this treatment is very expensive
(US$420 per course of treatment in Peru). Extensive and
mutilating mucosal lesions may arise years after the healing
of the primary cutaneous lesion. The mucosal lesions affect
the upper respiratory tract and may lead to the destruction
of nasopharyngeal cartilages and, consequently, to gross
mutilation and disﬁguration (Wijeyaratne et al. 1994).
First-line treatment of the mucosal disease is a 30-day
course of pentavalent antimonials at standard doses.
Amphotericin B is the most widely used second-line
treatment but the risk of severe adverse effects limits its use
to hospital settings (Crofts 1976; Llanos-Cuentas et al.
1997). Because treatment efﬁcacy with antimonials varies
according with the severity of the disease (Llanos-Cuentas
et al. 1997) and because relapses are not rare, a follow-up
period of 12 months is warranted during which the
evolution of the lesions is monitored. The most commonly
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after the end of treatment. Although MCL is generally
neglected by researchers and funding agencies (Davies
et al. 2003), limited efforts towards developing more
effective, safe and appropriate treatments for this disease
have been made.
According to reports by the Peruvian Ministry of Health
(MOH), San Martin de Pangoa is the district most affected
by MCL in the Satipo Province of Junin Department
(Figure 1). In 1999, the prevalence of the disease was 339
cases/100 000/year, almost twice the average prevalence of
192 cases/100 000/year in the province (source of cases:
UTES-Satipo). In December 2000, an assessment by
Me ´decinsSansFrontie `res(MSF)usingaconveniencesample
of 1096 persons, found 29 cases (13 cutaneous and 16
mucosal) considered as leishmaniasis based on the clinical
characteristics and the history of the lesion, yielding a point
prevalence of 2645 cases/100 000 inhabitants (Guthmann
et al. 2000). The disease predominantly affected migrant
agricultural workers who had moved to the area in recent
years. These ﬁgures suggested that the prevalence of the
diseasewashighinthegeneralpopulationofthedistrict,and
that a large number of patients remained untreated in the
most remote and inaccessible areas of the region. Moreover,
the assessment showed a number of deﬁciencies within the
national leishmaniasis control programme, such as insufﬁ-
cient and poorly trained personnel and inadequate stocks of
pentavalent antimonialstoensuretheadequatetreatmentof
all patients. In an effort to improve case management,
control activities were strengthened and developed with
participation of three institutions: the Peruvian MOH, the
Institute of Tropical Medicine of Universidad Peruana
Cayetano Heredia of Lima (IMT-UPCH) and MSF. In this
paper, we report the results of this project 2 years after its
initiation in January 2002.
Study area and brief description of the leishmaniasis
control program
San Martin de Pangoa is a rural area of 32 642 inhabitants
(2000 data) where the main economical activity is agricul-
ture (coffee, cacao, citrus and wood). The population lives
in small villages of a few hundred people, often isolated and
inaccessible by car during the rainy season (December to
March). Health care is provided through rural health posts
that each serve several villages and are run by a health
technician. The Leishmaniasis National Control Program
relies on the work done by the health technician at the
health post. Patients are ﬁrst diagnosed clinically by the
technician who makes a skin smear that is sent to the
laboratory in San Martin de Pangoa town. Parasitologically
conﬁrmed cases are treated if drugs are available. The
pentavalent antimonials are administered as daily injections
by the health technician at the health post for 20 (cutaneous
lesions) or 30 (mucosal lesions) days. Second-line treatment
with amphotericin B is only available at the hospital level.
The health technician is also responsible for the follow-up
of patients during and after the course of treatment
(6 months for cutaneous patients and 12 months for
mucosal patients), completion of the registers and reporting
to the central level. The activities of the health technician
are not limited to leishmaniasis, but include 18 other
programmes (malaria, tuberculosis, Expanded Programme
on Immunization, etc.). The workload thus generally
exceeds capacity, which leads to insufﬁcient quality of the
clinical diagnosis and of skin smears, poor supervision of
patients under treatment, lack of follow-up after the end of
the treatment and incomplete registration of patient
records. Moreover, the work and efforts made by the health
technicians are often not recognized by their supervisors. As
the working conditions are far from ideal (low salaries,
temporary contracts signed every month, lack of vacations,
no health insurance, etc.), the technicians are often under-
motivated and discouraged.
Objectives and activities
The general objective of the project involving these three
institutions was to decrease morbidity caused by MCL
through improved case management of patients in San Figure 1 Area of the project (•).
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supporting the technician at the different stages of the case
management process (diagnosis, treatment, follow-up and
keeping patient records), his/her motivation would increase
and the cycle no support–no motivation–low efﬁciency of
work would be broken. Each of the three institutions
involved in this project had a clearly deﬁned role. The work
was carried out by the MOH personnel (health and
laboratory technicians), in each of the MOH facilities (17
health posts, one laboratory and one reference hospital at
San Martin de Pangoa) with equipment and drugs given by
the MOH when available. The IMT-UPCH gave technical
support, participated in the training of health professionals
and technicians, supervised the laboratory and was avail-
able for management of severe cases. MSF provided a
support team of ﬁve persons (doctor, nurse, health techni-
cian, administrator and driver) whose main activities were:
training of health technicians; transport of the skin smears
to the laboratory; supply of medication for all leishmaniasis
patients once the diagnosis was made; supervision of the
overall activities and monthly reporting and statistical
follow-up of cases. Six speciﬁc objectives were deﬁned and
for each of them speciﬁc activities were implemented and
indicators were used to measure the results.
Case detection was improved. The health technicians
were asked to perform weekly visits to the villages. A
schedule was drawn up which included day of visit and
name of village. Radio announcements informed the
population in advance of scheduled visits. House-to-house
and school visits were conducted during which persons
were inspected and skin (and sometimes mucosal) lesions
were identiﬁed. The population was informed about the
clinical manifestations of the disease and asked to attend
the health facility in case of suspicion of leishmaniasis.
Diagnosis was improved. At the health post level, health
technicians were trained to identify and sample the skin
and mucosal lesions. The lab personnel was re-trained in
the staining and reading of the samples and the laboratory
was supplied with the necessary equipment (microscope,
reagents). A new sampling strategy was deﬁned,
incorporating a second skin smear (in case the ﬁrst was
negative) and the intradermal skin test (Davies et al. 1997).
The following classiﬁcation was used: a patient seen at the
health post by the technician with a dermal lesion and a
history of leishmaniasis was considered a suspected case of
leishmaniasis; if the presence of the parasite was conﬁrmed
through skin microscopical examination, the patient was
classiﬁed as a conﬁrmed case of leishmaniasis; when this
was not the case but the intradermal skin test was positive,
he/she was classiﬁed as a possible case of leishmaniasis; all
other patients for which the medical doctor considered
that both the clinical lesion and the history were very
suggestive of leishmaniasis were classiﬁed as probable
cases of leishmaniasis. All leishmaniasis cases
(conﬁrmed + possible + probable) were treated.
Patients’ access to treatment was improved through the
supply of health posts with ﬁrst-line drugs. Health techni-
cians were trained to calculate the correct treatment dosage
according to body weight and to adequately administrate
the drugs.
The referral process of severe patients to second level
structures was facilitated. Patient’s follow-up was im-
proved through the education of the patients and their
families. Patients were looked for in their own villages
when they did not report to the scheduled visits during
follow-up.
Data reporting was improved. Health technicians were
trained, new patient records were designed incorporating
data to be recorded on follow-up, registers were completed
monthly and kept up to date and regular reports were sent
to the provincial health authorities.
Under the initiative of MSF, representatives of MSF in
Peru, the Access to Essential Medicines Campaign of MSF,
the MOH and other national institutions explored the
possibility of making generic antimonials available as a
way to reduce the cost of anti-leishmanial therapy.
Results
Number of cases detected
The number of suspected cases identiﬁed by the health
technicians was 268 in 2001 and 326 in 2002, of which
240 (90%) and 254 (78%) were diagnosed as leishmaniasis
cases (either conﬁrmed, possible or probable) (Table 1).
There were signiﬁcant differences in prevalence between
villages. Of the 494 leishmaniasis cases, 51 (10%) were
mucosal: 12.1% (29/240) in 2001 and 8.2% (22/254) in
2002. Cases were reported throughout the year, with a
peak beginning in June (Figure 2). Considering only the
conﬁrmed cases (n ¼ 82 in 2001; n ¼ 153 in 2002), the
prevalence was 251 cases/100 000 in 2001 and 450 cases/
100 000 in 2002, respectively 1.3 and 2.3 times higher
than the year preceding the beginning of the project (193
cases/100 000/year in 2000).
Clinical and laboratory diagnosis
Of 240 cases diagnosed in 2001, 82 (34%) were conﬁrmed
cases for which the parasite was identiﬁed by microscopy,
26 (11%) were possible cases with a positive intradermal
skin test and a negative microscopy, and 132 (55%) were
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of leishmaniasis) (Table 2). In 2002, the proportion of
conﬁrmed cases increased to 60% (153/254), possible cases
remained stable (10%, or 24/254) and probable cases
decreased to 30% (77/254).
Access of patients to treatment
Among the 494 leishmaniasis cases diagnosed in both
years, 263 (53%) were treated with a pentavalent anti-
monial (110/240, 46% in 2001; and 153/254, 60% in
2002) (Table 2). The remaining cases (130 in 2001, 54%;
and 101 in 2002, 40%) did not receive any therapy because
they did not return to the health post and the team was not
able to ﬁnd the patient after the diagnosis had been made,
sometimes even after visiting his/her village of residence.
They were considered lost to follow-up before treatment
and involved both mucosal and cutaneous cases (19 and
212 cases for the period 2001–2002 respectively). Nineteen
of 231 (8%) cases who did not start antimonial therapy
Table 1 Number of diagnosed cases (conﬁrmed + possible + probable) and prevalence of leishmaniasis, San Martin de Pangoa District,
Satipo Province, Peru, January 2001 to December 2002 (source: MSF, Ministerio de Salud)
Villages
2001 2002
Population
Cases
Prevalence
rate* Population
Cases
Prevalence
rate* Cut Muco Tot Cut Muco Tot
Alto Kiatari 939 11 4 15 1597 955 7 1 8 837
Boca Kiatari 875 18 5 23 2628 890 6 4 10 1123
Campiruchiari 1302 7 1 8 691 1325 4 1 5 377
Chavini 1102 4 1 5 453 1121 1 0 1 89
Cubantia 995 5 0 5 502 1012 3 1 4 395
Fortaleza 499 10 0 10 2020 508 27 0 27 5315
Jerusalem M. 755 17 3 20 2781 768 10 3 13 1692
Matereni 1438 0 0 0 0 1463 1 0 1 68
Mazarun Quiari 1528 7 0 7 458 1554 0 0 0 0
Naylamp 1279 11 2 13 1016 1301 15 2 17 1306
San Antonio 1852 6 2 8 432 1884 3 1 4 212
San Cristobal 1094 7 0 7 640 1113 9 1 10 898
SJ Miraﬂores 1199 13 1 14 1167 1220 15 1 16 1311
SM Pangoa 5687 16 3 19 334 5785 22 2 24 414
San Ramon 4299 12 2 14 326 4373 10 1 11 251
SR de Alto Kiatari 708 10 1 11 1553 720 5 0 5 694
Tziriari 3340 32 3 35 1079 3398 53 1 54 1589
Union Chavini 1079 15 0 15 1390 1096 13 1 14 1277
Vilcabamba 1784 9 0 9 504 1815 9 1 10 551
Villa Maria 888 1 1 2 225 903 6 0 6 664
Rio Ene 855 13 1 14 1637
Total 32642 211 29 240 735 34059 232 22 254 745
* Number of cases per 100 000 population.
 The 2002 population was estimated using the Annual Growth Rate of 1.73% (source: INEI).
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Figure 2 Distribution of diagnosed cases of leishmaniasis (con-
ﬁrmed + probable + possible) by month, San Martı ´n de Pangoa
District, Satipo Province, Peru, January 2001 to December 2002
(source: MSF, Ministerio de Salud).
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for the period 2001–2002.
Patient follow-up during and after the treatment course
Among the 110 patients who were treated with antimoni-
als in 2001, seven (6%) did not complete the full treatment
course (30 days; all mucosal cases) because they inter-
rupted their therapy despite tracing by the team in their
villages. These were considered as lost to follow-up during
treatment (Table 2). They represented 19 patients of 153
(12%) in 2002 (three of which interrupted the therapy
because of secondary effects). Among the total number of
26 patients who did not complete treatment during the
period, nine (34%) were mucosal. These represented 28%
of the 32 mucosal cases who started treatment. A total of
237 patients (103 patients in 2001, 94%; 134 patients in
2002, 88%) completed the full treatment course (average
of 90% over the 2-year period).
Of 103 patients who completed the full treatment course
in 2001, 57 (55%) had a complete 6-month (cutaneous
cases) or 12-month (mucosal cases) post-treatment follow-
up. This percentage was 86 of 134 (64%) in 2002. The
percentage of lost to follow-up after treatment was 45% in
2001, 36% in 2002 and 40% for the 2-year period. Among
the 94 patients who were lost after treatment, 12 (13%)
were mucosal. These represented 52% of the 23 mucosal
cases who completed antimonial treatment.
Table 2 summarizes the general case management of
leishmaniasis patients from clinical suspicion to the end of
post-treatment follow-up. Of the 494 leishmaniasis cases
diagnosed during the period 2001–2002, only 237 (48%)
completed a full ﬁrst-line treatment course with pentava-
lent antimonials, and only 143 (29%) were correctly
followed from the day of diagnosis until the end of post-
treatment follow-up. This low proportion of patients
who were not correctly followed was particularly import-
ant for mucosal cases: of the 51 mucosal cases diagnosed,
only 11 (21%) were correctly followed for a period of
12 months after treatment. Of the 143 patients correctly
followed, 83 (58%) were considered cured at the end of
follow-up, 51 (36%) were not cured and were still in
follow-up, ﬁve (4%) were treatment failures, three (2%)
had been referred to the hospital and one (1%) had died.
Treatment cost
When the current project was initiated, the MOH was
using sodium stibogluconate (SSG, Viteco, Colombia) for
the price of 17 soles (US$5) per vial of 1.5 g/5 ml (data:
MOH). The drug cost for a full treatment course of a
cutaneous patient (3 vials/day for 20 days) was therefore
US$300 and closer to US$350–400 when additional costs
(i.e. equipment and supplies) are taken into account
(A. Llanos-Cuentas, personal communication). Following a
proposal of MSF, the MOH agreed to include a generic
SSG (from Albert David Ltd, India) in the list of critical
drugs of the MOH. This inclusion should signiﬁcantly
reduce costs and increase access to treatment. According
to MSF data (den Boer 2002; S. Lonlas, personal
communication), estimated costs for the treatment of one
cutaneous patient in Peru (including taxes and transpor-
tation) would be about one-sixth (approximately US$50)
of costs before the beginning of the project.
Discussion
In the 2-year period, the objectives of the project were
largely achieved. Considering only the conﬁrmed cases of
leishmaniasis, the number of patients increased threefold
Table 2 Number (%) of diagnosed cases
of leishmaniasis (conﬁrmed +
possible + probable), treated and
followed up, San Martin de Pangoa
District, Satipo Province, Peru, January
2001 to December 2002 (source: AASF,
Ministerio de Salud)
2001 2002 Total
Suspected cases 268 326 594
Leishmaniasis cases 240 254 494
Conﬁrmed 82 (34) 153 (60) 235 (48)
Possible 26 (11) 24 (10) 50 (10)
Probable 132 (55) 77 (30) 209 (42)
Lost to follow-up before beginning of treatment 130 (54) 101 (40) 231 (47)
Antimonial therapy 110 (46) 153 (60) 263 (53)
Completed 103 (94) 134 (88) 237 (90)
Lost to follow-up during treatment course 7 (6) 19 (12) 26 (10)
Follow-up after end of antimonial therapy
Completed follow-up* 57 (55) 86 (64) 143 (60)
Lost to follow-up after end of treatment* 46 (45) 48 (36) 94 (40)
* The denominator for proportions is the number who completed the treatment, i.e. 103 in
2001, 134 in 2002 and 237 for the 2-year period.
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the diagnosis improved, as shown by the signiﬁcant and
increasing proportion of leishmaniasis cases that were
conﬁrmed cases (34% in 2001, 60% in 2002); drugs were
always available, allowing the complete treatment of every
patient; the proportion of lost to follow-up during treat-
ment (10%) was low; the proportion of patients who
completed treatment and were correctly followed up
during the required period of time after the end of the
treatment was signiﬁcant (60%). To our knowledge, this is
the ﬁrst published experience showing the achievements of
a programme of detection, treatment and follow-up of
leishmaniasis patients in Latin America.
We believe that these achievements are because of three
major factors. First, to the resources that were put into this
project by MSF during the two-year period: salaries of the
team, rent of ofﬁce and house, purchase and maintenance
of a car, among major costs. Secondly, to the close
collaboration between the three institutions involved,
which permitted the mobilization of the leishmaniasis
control programme at all its steps. Finally, the cornerstone
was the constant availability of medications, which
underlies all the rest: the health technician guarantees the
patient that he/she will be always treated, and this creates a
new and closer relationship between the patient and the
care provider. Moreover, the patient suddenly realizes that
the health service is now able to respond to his/her need,
which had not been the case in the previous years when
recurrent shortages of drugs left a signiﬁcant number of
patients without treatment. The general consequence of all
this is an increased motivation of the health technician and
an improved efﬁciency of his work (better diagnosis, better
supervision, better reporting, etc.).
However, these achievements should not mask the real
difﬁculties that persisted. The proportion of lost to follow-
up before treatment was high (47%). Perhaps the lesions of
many of these patients healed spontaneously and these
people no longer felt the need to be treated. Additionally,
as cutaneous lesions are only slightly painful, patients do
not feel the need for medical consultation, especially as
they are busy in the ﬁelds. They are not prepared to lose
20–30 days of work to walk to the health facility for the
duration of a long and painful treatment. The proportion
of losses was also high after treatment (40%), which may
be explained by the socio-economic characteristics of the
population in this area. The affected people live in villages
isolated in the middle of the forest with poor access to
transportation, making them very difﬁcult to reach by the
health workers, who are understaffed and overloaded by
numerous tasks. The patients are usually migrant workers,
who may stay in the forest only for a period of a few weeks
or months before returning to their villages of origin
without waiting for the results of the parasitological
examination, or the end of the treatment (follow-up). The
higher proportion of losses during and after treatment for
mucosal compared with cutaneous cases could be ex-
plained by factors such as a the severity of the disease
(patients may have travelled to the city or may have sought
treatment in a hospital) and a worse prognosis (patients
may have died) in mucosal cases, a longer treatment course
in these patients (which could determine low adherence),
or ﬁnally by socio-economic factors related to a more
difﬁcult access to health care, information that was not
recorded in our setting.
New strategies should therefore be explored, for instance
based on a network of health workers at the village level
able to administer and supervise the treatment, and to
ensure follow-up. The availability of rapid and easy-to-use
diagnostics, and of efﬁcacious, safe and especially shorter
treatments that can easily be administered in local health
centres, or be taken home by the patients, would be a
major leap forward. For instance, a cheap and effective
topical treatment for cutaneous leishmaniasis (possibly to
complement with a short course systemic treatment) would
represent a major advance in the control and management
of this disease. Although there is still no strong evidence to
support this hypothesis, combination therapies should
increase the effectiveness of anti-leishmanial treatment in
particular by decreasing the duration of the course and
hence possibly its side-effects. Therefore, renewed research
and development efforts are needed for improved and more
appropriate treatments to speciﬁcally address the health
needs of the affected population.
An important achievement of this project is the intro-
duction of a generic brand of sodium stibogluconate (from
Albert David Ltd) in the MOH list of critical drugs. This
allows the importation into Peru and use of the cheaper
generic antimonial drugs, like several other countries are
already doing to increase access to this class of drugs. The
treatment of the 494 patients diagnosed in the district
during this 2-year period would have cost US$24 700 with
the generic drugs (US$50/patient) instead of US$148 200
with currently used branded drugs (US$300/patient). If we
consider the 8764 patients diagnosed in Peru in 2002
(MOH) and assume that all these patients had cutaneous
leishmaniasis, the savings resulting from the use of a
generic SSG would be US$2.191 million. This money could
then be invested in salaries and training of more health
workers to develop a better network for the early detection
and follow-up of leishmaniasis cases at the village level.
As demonstrated in other countries, and in other diseases
as well, the use of cheaper generic medications can
dramatically contribute to improve access to an effective
treatment, especially for the most impoverished
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that this is the way forward and that all actors, patients,
health workers, NGOs and international organizations
should advocate for the use of generic medications, while
simultaneously call for needs-driven research and develop-
ment for more appropriate drugs to tackle the needs of
neglected populations. Government should base their drug
policy on the effective use of these cheaper medications, and
use the budget saved to invest in support or strengthening
programmes such as the one implemented in Satipo.
Conclusions
The work of these three institutions in collaboration
permitted a considerable improvement in the case man-
agement of patients affected by leishmaniasis in San Martin
de Pangoa District, Peru. The registration of a generic
pentavalent antimonial should allow the treatment of a
signiﬁcant number of additional patients, while saving
money to invest in other facets of the case management.
Difﬁculties encountered highlight the need to further
strengthen the programme, particularly through improved
case ﬁnding and follow-up of patients. Better treatments
are also needed (more effective, safer, shorter and more
easy to use). We believe this experience is important both
because of its strategy and results, which are of interest for
institutions and health services involved with this disease
that afﬂicts the world poorest population and is so much
neglected by donors.
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